
    
      The study is a prospective, single center clinical trial to establish the efficacy of NuCel,
      a minimally manipulated allograft tissue, for use in lumbar interbody and intertransverse
      fusion procedures. Subjects will undergo standard interbody fusion surgery as per the signed
      informed consent with NuCel and autograft bone. Patients will be evaluated postoperatively at
      6 weeks, 3 months, 6 months, 1 year, and 2 years (if required).
    
  